Pretreatment fatigue can mean worse survival outcomes for patients with cancer

Patients with cancer who reported clinically significant fatigue at the start of their treatment had shorter overall survival times and more side effects than patients without fatigue. Those are the findings of a new analysis of patients who took part in four clinical trials testing treatments for lung cancer or prostate cancer conducted by the SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).